---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-003854"
form_type: "8-K"
ticker: "FRMM"
cik: "0001690080"
company_name: "FORUM MARKETS Inc"
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-10T00:04:21.254777+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 180 Life Sciences receives Nasdaq non-compliance notice over shareholder approval for offering

## Summary
- Received Nasdaq notice on Oct 11, 2023 for violating Listing Rule 5635(d) requiring shareholder approval.
- Offering involved 666,925 shares at $0.65, pre-funded warrants for 3.95M shares at $0.6499, and 4.62M common warrants.
- Nasdaq ruled that the best-efforts offering with one investor buying 98% was not a public offering.
- No immediate impact on listing; Company has 45 days to submit a plan, with possible 180-day extension.
- Company intends to submit a compliance plan but cannot guarantee acceptance or regaining compliance.

## SEC filing metadata
- accession: 0001013762-23-003854
- form_type: 8-K
- ticker: FRMM
- cik: 0001690080
- company_name: FORUM MARKETS Inc
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690080/000101376223003854/0001013762-23-003854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690080/000101376223003854/ea186707-8k_180life.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-003854
- JSON: https://secwatch.observer/filing/0001013762-23-003854.json
- Plain text: https://secwatch.observer/filing/0001013762-23-003854.txt

## Key facts
- Listing & Compliance Notices
  FORUM MARKETS Inc received a nasdaq deficiency notice notice regarding other (rules 5635(d)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5635(d)
  source text: of Nasdaq’s shareholder approval rules due to the type of offering, a best efforts offering pursuant to a placement agency agreement, and the fact that one investor purchased 98% of the Offering. As a result, because the Offering represented greater than 20% of the Common Stock outstanding and was priced below the Minimum Price, the Staff determined that
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690080/000101376223003854/0001013762-23-003854-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.